CMS Just Ended Medicaid Funding for Kids’ Gender Transitions. Here’s What Actually Changes.
- Aug. 11, 2026 the date CMS Administrator Dr. Mehmet Oz and HHS Secretary Robert F. Kennedy Jr. finalized the rule ending federal Medicaid and CHIP funding for “sex-rejecting procedures” on minors — Fox News Politics, Aug. 11, 2026
- Oct. 13, 2026 the effective date — minors already on hormone therapy get up to a 6-month taper, running through roughly April 2027 — STAT News, Aug. 11, 2026
- $235M CMS's own projected 10-year Medicaid and CHIP savings ($138M federal, $97M state) — roughly 0.002% of a decade of combined program spending — STAT News; CMS regulatory-impact analysis
- 27 States already ban gender-affirming care for minors outright; the Supreme Court upheld Tennessee's ban in United States v. Skrmetti, 2025 — STAT News, Aug. 11, 2026
- ~17 States Medicaid programs that, before this rule, still covered some gender-affirming care for minors — STAT News, Aug. 11, 2026
On August 11, 2026, the Centers for Medicare & Medicaid Services finalized a rule ending federal Medicaid and CHIP funding for what the agency calls “sex-rejecting procedures” — puberty blockers, cross-sex hormones, and surgeries — for anyone under 18 on Medicaid or under 19 on CHIP. CMS Administrator Dr. Mehmet Oz and HHS Secretary Robert F. Kennedy Jr. announced it together, eight months after the agency first proposed it.
The rule does not ban the procedures outright, and it leaves mental-health treatment for gender dysphoria untouched — that stays covered. States and private insurers remain free to pay for hormone therapy or surgery for a minor with their own money. What changes is narrower: federal Medicaid and CHIP dollars will no longer reimburse it, starting October 13, 2026, with up to a six-month taper for minors already receiving hormone therapy.
CMS and HHS frame the rule as following the medical evidence, pointing to the United Kingdom’s 2024 Cass Review and the agency’s own regulatory-impact analysis. Advocacy and medical groups — GLAD Law, the Human Rights Campaign, and the American Academy of Pediatrics — call it political interference in decisions they say belong to doctors and families. Both positions are on the record below.
The rule finalized August 11 traces to a proposal CMS published in the Federal Register on December 19, 2025 — document 2025-23464 — alongside a companion rule, document 2025-23465, applying a parallel Medicare Condition of Participation to hospitals that treat minors with these procedures. After roughly eight months of public comment, CMS adopted the final rule largely as proposed: it takes effect October 13, 2026, with a taper running through roughly April 2027 for minors already on hormone therapy.
“Today, we are ending federal taxpayer funding for sex-rejecting procedures on children... The federal government will no longer use Medicaid and CHIP dollars to fund procedures that fail to meet the evidentiary standard our children deserve.”
HHS Secretary Robert F. Kennedy Jr. · Aug. 11, 2026
The proposal traces to a directive President Trump (R) gave Dr. Mehmet Oz earlier in his term, instructing CMS to review the government’s role in funding pediatric gender-transition care. Oz, a Trump-endorsed 2022 Republican U.S. Senate nominee in Pennsylvania before Trump named him to run CMS, has cast the rule as the agency following, not setting, the medical evidence. Trump himself weighed in on the finalized rule in a Truth Social post.
We are not going to pay for our innocent children to undergo these barbaric surgeries and practices, which result in unthinkable and irreversible harm to their young bodies.
Paraphrased commentary · not a verbatim post
Truth Social · paraphrasing President Trump's public reaction to the final rule
CMS’s regulatory-impact analysis leans heavily on the United Kingdom’s 2024 Cass Review, the independent inquiry commissioned by England’s National Health Service that found the evidence behind puberty blockers and cross-sex hormones for minors to be of low quality, and that led the NHS to restrict the treatments for most patients under 18 outside clinical trials. CMS’s rule adopts a similar posture for U.S. federal dollars: it does not declare the treatments illegal, only that Medicaid and CHIP will no longer pay for them absent stronger evidence.
“By cutting off federal funds for these sex-rejecting procedures, we're following the science, saving taxpayer dollars, and, most importantly, protecting children from potentially irreversible harm so they can truly flourish.”
Dr. Mehmet Oz · CMS Administrator · Aug. 11, 2026
What the rule does not touch matters as much as what it does. Mental-health counseling and treatment for gender dysphoria remain Medicaid- and CHIP-eligible. And the funding restriction applies only to federal dollars: a state Medicaid program or a private insurer can still cover puberty blockers, hormones, or surgery for a minor using its own money — CMS is withdrawing federal reimbursement, not issuing a nationwide ban.
CMS’s own regulatory-impact analysis projects the rule will save $235 million combined across Medicaid and CHIP over ten years — $138 million in federal spending, $97 million picked up by states. Measured against a decade of combined Medicaid and CHIP spending, that figure works out to roughly two-thousandths of one percent — a rounding error against the programs’ total budget. CMS has not presented this as a significant fiscal fix, and the numbers do not support treating it as one.
That leaves the evidentiary argument, not the budget, as the rule’s actual substance. Kennedy and Oz built their public case on the Cass Review and CMS’s own clinical findings, not on cost savings; the savings figure appears in the regulatory filing because federal rulemaking requires one, not because it drove the policy.
The federal funding change lands on ground already reshaped by state law and the courts. Twenty-seven states now ban gender-affirming care for minors outright, regardless of who is paying. The Supreme Court upheld the leading example, Tennessee’s ban, in United States v. Skrmetti in 2025, rejecting the argument that the law amounted to unconstitutional sex discrimination. Roughly 17 state Medicaid programs, by contrast, still covered some gender-affirming care for minors before CMS’s rule — those are the programs most directly affected by the funding change.
CMS’s final rule is a distinct action from an earlier fight over the same underlying subject. In December 2025, when CMS first proposed this rule, New York Attorney General Letitia James (D) led a coalition of 18 other Democrat-led jurisdictions — California, Colorado, Connecticut, Delaware, Illinois, Maine, Maryland, Massachusetts, Michigan, Minnesota, New Jersey, New Mexico, Oregon, Rhode Island, Vermont, Wisconsin, Washington, and the District of Columbia — in a lawsuit against a separate, earlier HHS declaration on youth gender care. That suit did not target the rule CMS finalized August 11; it remains a distinct piece of litigation over a different agency action.
Medical and advocacy groups condemned the final rule the same day CMS announced it. GLAD Law legal director Josh Rovenger argued the rule inserts the federal government between families and their doctors.
“[The rule] is putting up barriers between parents and their ability to make the best medical decisions for their children.”
Josh Rovenger · Legal Director, GLAD Law · Aug. 11, 2026
The Human Rights Campaign, led by President Kelley Robinson, put out a statement casting the rule as part of a broader pattern of restrictions on transgender health care access — the latest in a series of administration actions rather than an isolated policy. The American Academy of Pediatrics, under President Dr. Susan Kressly, and the American Medical Association, represented by Dr. David Aizuss, issued a joint statement disputing CMS’s reading of the underlying science.
“[The] claims [in the underlying HHS review] are rooted in politics and partisanship, [and] misrepresent the consensus of medical science.”
AAP President Dr. Susan Kressly & AMA's Dr. David Aizuss · joint statement
CMS has not disputed that its reading of the evidence is contested. Oz and Kennedy’s position is that the agency is entitled to set its own evidentiary bar for what federal dollars fund, and that the underlying science remains unsettled enough that taxpayer money should not be presumed to follow it. Both sides agree on what changed October 13, 2026; they disagree entirely on whether it should have.
On August 11, 2026, CMS Administrator Dr. Mehmet Oz and HHS Secretary Robert F. Kennedy Jr. finalized a rule ending federal Medicaid and CHIP funding for puberty blockers, cross-sex hormones, and surgeries for minors, effective October 13, 2026, with a taper for those already in treatment. Mental-health care for gender dysphoria stays covered, and states and private insurers can still pay for the procedures with their own money — only federal reimbursement changes. CMS cites the UK’s Cass Review and its own evidence review as the basis; the projected $235 million in decade savings is a fraction of a percent of Medicaid and CHIP spending, not the driving rationale. Medical and advocacy groups dispute CMS’s reading of the science and call the rule an intrusion on family medical decisions. Both the evidentiary dispute and the political one are now on the record.
